Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daily carboplatin plus thoracic radiotherapy followed by durvalumab in vulnerable unresectable stage III NSCLC
jRCTs031190070Phase 2Completed
- Sponsor
- North East Japan Study Group
- Start
- Sep 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and carboplatin in non-small cell lung cancer (NSCLC), sponsored by North East Japan Study Group. Primary endpoint: Progression-free survival rate at 12 months from secondary registration. Started Sep 2019; status: completed.
02
Drugs
durvalumabcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031190070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190070.